PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
GSK’s plan to bring blood cancer drug Blenrep (belantamab mafodotin) back to markets has hit a stumbling block, after the …
With tighter budgets, regulatory challenges, and uncertainty from tariffs, pharmaceutical companies are turning to third-party logistics (3PL) suppliers to deliver …
Oslo, Norway-headquartered Navamedic has completed its previously announced acquisition of dne pharma's business for Nkr225m ($22m). This acquisition comprises dne pharma's …
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery …
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing …
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in …
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows a …
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening …
Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) as an adjunct to diet and …
The World Health Organization (WHO) is recommending the use of Gilead Sciences’ newly approved injectable version of lenacapavir to fight …
A robust supply chain is the backbone of stable growth, making it a critical area of concern for small pharma …
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor …
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) …